![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB | |
|
PDF (Supplementary Data)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
53kB |
| Item Type: | Article |
|---|---|
| Title: | Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD |
| Creators Name: | Cree, B.A.C. and Bennett, J.L. and Kim, H.J. and Weinshenker, B.G. and Pittock, S.J. and Wingerchuk, D. and Fujihara, K. and Paul, F. and Cutter, G.R. and Marignier, R. and Green, A.J. and Aktas, O. and Hartung, H.P. and Williams, I.M. and Drappa, J. and She, D. and Cimbora, D. and Rees, W. and Ratchford, J.N. and Katz, E. |
| Abstract: | BACKGROUND: In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. OBJECTIVE: To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses. METHODS: N-MOmentum is a prospective, randomized, placebo-controlled, double-masked trial of inebilizumab, an anti-CD19 monoclonal B-cell-depleting antibody, in patients with NMOSD. Pre-planned and post hoc analyses were performed to evaluate the primary endpoint across a range of attack definitions and demographic groups, as well as key secondary endpoints. RESULTS: In the N-MOmentum trial (ClinicalTrials.gov: NCT02200770), 174 participants received inebilizumab and 56 received placebo. Attack risk for inebilizumab versus placebo was consistently and significantly reduced, regardless of attack definition, type of attack, baseline disability, ethnicity, treatment history, or disease course (all with hazard ratios < 0.4 favoring inebilizumab, p < 0.05). Analyses of secondary endpoints showed similar trends. CONCLUSION: N-MOmentum demonstrated that inebilizumab provides a robust reduction in the risk of NMOSD attacks regardless of attack evaluation method, attack type, patient demographics, or previous therapy.The N-MOmentum study is registered at ClinicalTrials.gov: NCT2200770. |
| Keywords: | Attack Risk, Clinical Trial, Devic's Disease, Inebilizumab, Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Patient Demographics, Sensitivity Analyses |
| Source: | Multiple Sclerosis Journal |
| ISSN: | 1352-4585 |
| Publisher: | Sage Publications |
| Volume: | 27 |
| Number: | 13 |
| Page Range: | 2052-2061 |
| Date: | 1 November 2021 |
| Official Publication: | https://doi.org/10.1177/1352458521988926 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
